Literature DB >> 18158863

Advances in the genetics of Parkinson's disease.

Serena Rosner1, Nir Giladi, Avi Orr-Urtreger.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder affecting a significant proportion of the ageing population. The etiology is unknown and it is likely due to a multifactorial interaction of genes and the environment on the background of ageing. Findings in the last decade suggest that the contribution of genetics to familial forms of PD is much greater than previously appreciated. Twelve loci are now associated with highly penetrant autosomal dominant or recessive PD, and causative mutations have been identified in eight genes with mutation carriers often characterized by a phenotype indistinguishable from idiopathic disease. To date, PD pharmacotherapy is symptomatic only and does not slow disease progression. Understanding how genetic mutations cause familial PD is likely to clarify molecular mechanisms underlying PD in general and will provide a guide for the development of novel therapies, both preventative and palliative, applicable to all forms of parkinsonism. This review outlines the advances in the study of the genetic background of PD and their possible clinical implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18158863     DOI: 10.1111/j.1745-7254.2008.00731.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Authors:  Ilan Halperin; Micaela Morelli; Amos D Korczyn; Moussa B H Youdim; Silvia A Mandel
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

3.  Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.

Authors:  Silvia A Mandel; Micaela Morelli; Ilan Halperin; Amos D Korczyn
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

Review 4.  Autoimmunity, dendritic cells and relevance for Parkinson's disease.

Authors:  E Koutsilieri; M B Lutz; C Scheller
Journal:  J Neural Transm (Vienna)       Date:  2012-06-15       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.